Breaking the cycle of excitotoxicity: blood glutamate scavenging provides robust neuroprotection in spinal cord injury
The cBGS platform represents a first-in-class systemic neuroprotective therapy that effectively mitigates glutamate excitotoxicity and secondary injury following SCI. Its robust efficacy, wide therapeutic window, and favorable safety profile support its strong potential for clinical translation in acute SCI and other excitotoxicity-driven neurotrauma conditions, where no effective treatments currently exist.
Authors
- Evgeni Banyas
- Amit Benbenishty (ORCID: https://orcid.org/0000-0003-4559-5821)
- Yona Goldshmit
- Rosemary Lavender
- Alex Yakovchuk
- Angela Ruban
- Josef Levin
- Ruth Baltovska
Institutions
- Tel Aviv University (IL)
- Australian Regenerative Medicine Institute (AU)
- Edna Pasher Ph.D & Associates (Israel) (IL)
Publication Details
- Journal
- Inflammation and Regeneration
- Published
- 2026-02-27
- DOI
- https://doi.org/10.1186/s41232-026-00411-x
- Primary Topic
- Spinal Cord Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00